Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team
September 16 2021 - 7:30AM
Dante Labs, a global leader in genomics and precision medicine,
today announced the appointment of Rachel Haverfield to the
company’s leadership as General Counsel to drive the growth and
scale of the business and opportunity.
“We are so pleased to have Rachel joining Dante’s growing
leadership of top talent in the industry,” said Andrea Riposati,
CEO of Dante Labs. “Rachel’s global, legal commercial, regulatory
and compliance expertise will be instrumental to Dante Labs as we
empower governments, patient groups and individuals worldwide with
actionable, clinically-relevant whole genome based insights and
personalized medicine.”
Rachel Haverfield joins Dante Labs as General Counsel. As a
dynamic international in-house lawyer with major law firm, public
and private company experience, Rachel will serve as principal
legal advisor and manager on all transactions, intellectual
property matters, corporate governance, mergers and acquisitions at
Dante Labs. Prior to joining Dante, Rachel was Vice President of
Legal EMEA at Illumina based in Cambridge.
“I’m thrilled to be joining Dante Labs at this exciting time
when genomics is emerging as essential to healthcare and is
resulting in better outcomes for patients,” said Rachel Haverfield,
General Counsel of Dante Labs. “I’m excited to join this team of
experts aligned in our mission to scale the business globally in
order to bring a more human approach to healthcare.”
About Dante LabsDante Labs is a
global genomic data company building and commercializing a new
class of transformative health and longevity applications based on
whole genome sequencing and AI. Our assets include one of the
largest private genome databases with research consent, a
proprietary software platform designed to unleash the power of
genomic data at scale and proprietary processes which enable an
industrial approach to genomic sequencing.
Headquartered in Cambridge, United Kingdom, with
a research laboratory in Wolverhampton, Dante Labs supported the UK
Government’s urgent requirement to scale-up a high-capacity, highly
automated testing solution for Covid-19, including infected
patients as well as those with antibodies. Dante Labs was able to
deliver by leveraging existing technology that had been developed
for whole genome sequencing.
ContactGiorgio Lodimedia@dantelabs.com+39 0862
191 0671www.dantelabs.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024